Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium
Pittsboro, NC – September 16, 2023
Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced today that its founder, Christopher Crean, presented groundbreaking research on Kv7 prodrugs at the recent Kv7 Symposium held in Naples, Italy from September 13-15, 2023. The symposium brought together leading experts in ion channel pharmacology to discuss the latest advancements in Kv7-targeted drug development.
Mr. Crean’s presentation focused on Xyzagen’s work in developing Kv7 prodrugs, a new class of compounds designed to treat neurological conditions such as epilepsy, chronic pain, and other ion channel-related diseases. These prodrugs demonstrated promising results in preclinical studies, showing potential to enhance the efficacy and specificity of Kv7 channel modulators. These prodrugs are based on ezogabine, that was a first in class antiepileptic drug that targeted Kv7.2/7.3. Ezogabine was removed from the market place due to poor sales in the adjunctive therapy space for epilepsy because it was a three times a day therapy in a once a day space. Xyzagen’s programs have changed the pharmacokinetic profile of ezogabine to allow it to be injected for acute use and also have altered the first pass metabolism, allowing more active drug to be absorbed and thus reduce drug burden.
“We were excited to present our research at the Kv7 Symposium, where we had the opportunity to showcase the potential of Kv7 prodrugs to significantly impact the treatment of neurological disorders,”
said Christopher Crean, Founder and CEO of Xyzagen. “Our work represents a major step toward advancing therapies that could offer new hope to patients with conditions that have few effective treatment options.”
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.
Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
